Literature DB >> 24693366

The Prevalence of Toxoplasma gondii in Hemodialysis Patients.

Masomeh Bayani1, Amrollah Mostafazadeh2, Farsheed Oliaee3, Narges Kalantari4.   

Abstract

Entities:  

Keywords:  Kidney Failure, Chronic; Renal Dialysis; Toxoplasma

Year:  2013        PMID: 24693366      PMCID: PMC3950778          DOI: 10.5812/ircmj.5225

Source DB:  PubMed          Journal:  Iran Red Crescent Med J        ISSN: 2074-1804            Impact factor:   0.611


× No keyword cloud information.
Dear Editor, Toxoplasma gondii (T. gondii) is an obligate intracellular protozoan parasite that can infect a wide range of hosts including humans. Humans are infected through raw or undercooked meat containing tissue cysts and ingesting oocysts through contaminated food, water supplies and gardening. Infection with T. gondii is characterized by acute and chronic phases, which are distinct with regards to the developmental stage of the parasite and the sites of parasite persistence (1). However, Toxoplasma infection is mostly asymptomatic in immunocompetent individuals but it may be life threatening in immunocompromised cases (2). There is some evidence that chronic renal failure patients undergoing hemodialysis are susceptible to acquire various infections (3). This study aimed to illustrate the clinical manifestations of toxoplasmosis in haemodialysis patients and seroconversion rates of T. gondii. The subjects were all haemodialysis patients admitted to the haemodialysis unit at Shahid Beheshti Hospital of Babol University of Medical Sciences, Babol, northern Iran and 50 healthy volunteers. Individuals with normal creatinine, blood urea nitrogen (BUN) and without any renal disease were randomly enrolled in this study. In addition to demographic data, period of haemodialysis treatment and any manifestation of acute toxoplasmosis such as fever of unknown origin, lymphadenopathy and encephalitis were recorded. Two milliliters blood was taken from each participants, serum was separated and then the existence of anti-T. gondii antibodies, IgG and IgM were measured using a commercial enzyme-linked Immunosorbent assay (ELISA) kit (Trinity Biotech Captia, USA). The tests were carried out according to the manufacture's recommendation. Five out of 18 seronegative cases were died and three out of 18 seronegative cases received renal transplant. One seronegative case of the healthy volunteer was not participated in the second experiment. The data were analyzed by t-test and Fisher's test. The average age of patients and the control group was 42.5 ± 11.5 and 34.8 ± 10.4, respectively. Fifty four out of 90 (60%) haemodialysis patients and 20 out of 50 (40%) healthy volunteers were female. The mean duration of dialysis was 5 ± 4.5 years. Seventy two out of 90 (80%) patients and 38 out of 50 (76%) healthy voluntaries were positive for Anti-T. gondii (IgG). No statistically significant difference was found between two groups (P > 0.05). IgM antibodies were not found in any of the cases among both groups in the first series of the experiment. In the second experiment which was carried out on seronegative cases, IgG and IgM, were detected in eight and two out of ten serum samples among haemodialysis patients, while IgG antibodies were detected in one serum sample within healthy volunteer group. There was a significantly higher seroconversion rate in chronic renal failure patients group and healthy volunteer group (80% versus 11.1%) (P = 0.002). Data obtained from the assessment of haemodialysis treatment duration and having anti-T. gondii antibodies showed that no relationship was seen between period of haemodialysis and the rate of seropositivity (P = 0.961). The demographic information data are presented in Table 1. Regular physical examination of haemodialysis patients did not demonstrate any manifestation of acute Toxoplasma infection due to reactivation of the parasite or recent infection.
Table 1.

Gender and Residency-Related Prevalence of IgG Antibodies to Toxoplasma Gondii in Haemodialysis Patient and Healthy Volunteers Groups

Groups (variable)Haemodialysis Patients Group, No. (%)Healthy volunteer Group, No. (%)
PositiveNegativePositiveNegative
Gender
Female46 (51.1%)8 (8.9%)13 (26%)7 (14%)
Male26 (28.9%)10 (11.1%)25 (50%)5 (10%)
Total72 (80%)18 (20%)3812
Residency 12 (24%)
Urban33 (36.7%)18 (20%30 (60%)0 (0%)
Rural29 (32.3%)10 (11%)8 (16%)
Total72283812
The findings obtained from the current study demonstrated a high rate of T. gondii infection in haemodialysis patients (80%) and healthy volunteers (76%), in comparision with the other studies (4). Risk factor variety predisposing to Toxoplasma infection such as age, climate conditions, agriculture activity, occupation and eating habits are the possible explanations for these differences (5, 6). Furthermore, assessment of anti-Toxoplasma antibodies in seronegative cases after one year showed that haemodialysis patients are at risk of infection either due to recent infection or reactivation of the parasite. Moreover, the percentage of seropositivity among females was significantly higher in the patient group but it was reverse in control group. Some researchers did not find a significant relationship between Toxoplasma infection rate and gender (7) whereas some other studies found it (6). Different sampling methods, diverse life styles, or gender differences in different communities could explain this diversity. Also, a non-significant difference was seen between seropositivity of patients who lived in rural areas compared with urban areas. On the other hand, this study did not demonstrate any manifestation of toxoplasmosis in the patients during regular physical examinations throughout a year. Nonspecific symptoms in toxoplasmosis e.g. fever is a possible reason for misdiagnosis or forgotten the Toxoplasma infection (8). Another possibility is the production of same cytokines in Toxoplasma infection and haemodialysis patients such as Interleukin 12 (IL-12) which plays a major anti-Toxoplasma role during the acute phase of the infection. Also, production of IL-2, IL-4 and IL-10 which are required for the development of resistance to the infection was increased in haemodialysis patients (9, 10). Therefore, this study does not recommend regular serological tests for haemodialysis patients except who are candidate for kidney transplant.
  10 in total

1.  Seroepidemiology of toxoplasmosis in amerindians from western Venezuela.

Authors:  L Chacin-Bonilla; Y Sanchez-Chavez; F Monsalve; J Estevez
Journal:  Am J Trop Med Hyg       Date:  2001-08       Impact factor: 2.345

2.  Identification of T helper cell subsets in continuous ambulatory peritoneal dialysis patients.

Authors:  T Yokoyama; K Nitta; K Futatsuyama; T Hayashi; K Honda; K Uchida; A Kawashima; W Yumura; H Nihei
Journal:  Nephron       Date:  2001-10       Impact factor: 2.847

Review 3.  Immune response to Toxoplasma gondii.

Authors:  Denis Filisetti; Ermanno Candolfi
Journal:  Ann Ist Super Sanita       Date:  2004       Impact factor: 1.663

Review 4.  Disturbances of acquired immunity in hemodialysis patients.

Authors:  Theodoros Eleftheriadis; Georgia Antoniadi; Vassilios Liakopoulos; Charalambos Kartsios; Ioannis Stefanidis
Journal:  Semin Dial       Date:  2007 Sep-Oct       Impact factor: 3.455

Review 5.  Toxoplasmosis: A history of clinical observations.

Authors:  Louis M Weiss; Jitender P Dubey
Journal:  Int J Parasitol       Date:  2009-02-13       Impact factor: 3.981

6.  Seroepidemiology of toxoplasmosis in renal patients.

Authors:  Veeranoot Nissapatorn; Teoh Hoe Leong; Rogan Lee; Jamaiah Ibrahim; Tan Si Yen
Journal:  Southeast Asian J Trop Med Public Health       Date:  2011-03       Impact factor: 0.267

Review 7.  Serodiagnosis of toxoplasmosis. The impact of measurement of IgG avidity.

Authors:  Maija Lappalainen; Klaus Hedman
Journal:  Ann Ist Super Sanita       Date:  2004       Impact factor: 1.663

8.  Seroepidemiology of Toxoplasma gondii infection in Isfahan province, central Iran: A population based study.

Authors:  Sayed Nasser Mostafavi; Behrooz Ataei; Zari Nokhodian; Majid Yaran; Anahita Babak
Journal:  J Res Med Sci       Date:  2011-04       Impact factor: 1.852

9.  Recently acquired Toxoplasma gondii infection, Brazil.

Authors:  Jeffrey L Jones; Cristina Muccioli; Rubens Belfort; Gary N Holland; Jacquelin M Roberts; Claudio Silveira
Journal:  Emerg Infect Dis       Date:  2006-04       Impact factor: 6.883

10.  Latent toxoplasmosis and human.

Authors:  A Dalimi; A Abdoli
Journal:  Iran J Parasitol       Date:  2012       Impact factor: 1.012

  10 in total
  7 in total

1.  Prevalence of toxoplasmosis and related risk factors among humans referred to main laboratories of Urmia city, North West of Iran, 2013.

Authors:  Mohammad Sadaghian; Sasan Amani; Rasool Jafari
Journal:  J Parasit Dis       Date:  2014-08-31

2.  Association between Toxoplasma gondii exposure and paediatrics haematological malignancies: a case-control study.

Authors:  Narges Kalantari; Javad Rezanejad; Ahmad Tamadoni; Salman Ghaffari; Jaber Alipour; Masomeh Bayani
Journal:  Epidemiol Infect       Date:  2018-08-10       Impact factor: 4.434

3.  Screening Methods for Active Toxoplasmosis in Animal Blood Samples.

Authors:  Mohammad Ali Mohaghegh; Hossein Hooshyar; Mohsen Ghomashlooyan
Journal:  Jundishapur J Microbiol       Date:  2016-03-05       Impact factor: 0.747

Review 4.  A systematic review and meta-analysis of the prevalence of toxoplasmosis in hemodialysis patients in Iran.

Authors:  Masoud Foroutan; Ali Rostami; Hamidreza Majidiani; Seyed Mohammad Riahi; Sasan Khazaei; Milad Badri; Elham Yousefi
Journal:  Epidemiol Health       Date:  2018-04-23

5.  Serological and Molecular Diagnosis of Toxoplasma gondii Infections in Thalassemia Patients.

Authors:  Hooman Hanifehpour; Seyed Kamal Samsam Shariat; Mohammad Saleh Ghafari; Farnaz Kheirandish; Vafa Saber; Shirzad Fallahi
Journal:  Iran J Parasitol       Date:  2019 Jan-Mar       Impact factor: 1.012

6.  Seroprevalence and associated risk factors of Toxoplasma gondii infection in patients undergoing hemodialysis and healthy group.

Authors:  Shahrzad Soltani; Mehdi Sagha Kahvaz; Sheyda Soltani; Fatemeh Maghsoudi; Masoud Foroutan
Journal:  BMC Res Notes       Date:  2020-12-07

7.  Is COVID-19 associated with latent toxoplasmosis?

Authors:  Salman Ghaffari; Narges Kalantari; Tahmineh Gorgani-Firouzjaee; Masomeh Bayani; Farzaneh Jalali; Meysam Aghajani Daroonkola
Journal:  Environ Sci Pollut Res Int       Date:  2021-10-25       Impact factor: 4.223

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.